Biotech Values

[DewDiligence]

IDIX—Steven Projan, one of NVS’ three directors on IDIX’s BoD (#msg-49743604) resigned two days ago, according to an 8-K filing today:

http://sec.gov/Archives/edgar/data/1093649/000095012310077353/c04899e8vk.htm

Insofar as NVS is contractually entitled to appoint three directors to IDIX’s BoD, I presume that NVS will soon name a replacement for Projan.

In the same 8-K filing, IDIX disclosed that general counsel, John Weidenbruch, is leaving effective 8/31/10 to work for another biotech company in Cambridge, MA whose identity has not been disclosed.